According to the current guidelines, however, families of prostate cancer patients found to carry a germline BRCA2 mutation would not fulfil the criteria for genetic testing until a median of two further breast and/or ovarian cancer cases per family occur.75 The identification of an inherited mutation in a prostate cancer patient would not only have implications for the patient, but should also be followed by genetic testing in all related family members, providing the opportunity for early cancer-specific screening and risk reduction strategies in those found to be carriers. The gene discussed is BRCA2; the disease is prostate carcinoma.